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FoxA and LIPG endothelial lipase control the uptake
of extracellular lipids for breast cancer growth
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The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth
are poorly understood. Here we report that BCa cells are dependent on a mechanism
to supply precursors for intracellular lipid production derived from extracellular sources and
that the endothelial lipase (LIPG) fulﬁls this function. LIPG expression allows the import of
lipid precursors, thereby contributing to BCa proliferation. LIPG stands out as an essential
component of the lipid metabolic adaptations that BCa cells, and not normal tissue,
must undergo to support high proliferation rates. LIPG is ubiquitously and highly expressed
under the control of FoxA1 or FoxA2 in all BCa subtypes. The downregulation of either LIPG or
FoxA in transformed cells results in decreased proliferation and impaired synthesis of
intracellular lipids.
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C
ancer cells undergo metabolic reprogramming in order to
produce biosynthetic precursors, such as ATP, lipids,
nucleotides and amino acids, which are required to sustain
the energy and substrate demands for rapid growth and
proliferation1,2. Among the various metabolic deregulations in
cancer, lipid metabolism emerges as a critical pathway for
the maintenance of cell survival, growth and migration3.
Thus research devoted to understanding the mechanisms
of lipid metabolism adaptation in breast cancer (BCa) is
highly relevant if we are to devise novel strategies to improve
the control of this disease.
The FoxA protein sub-family belongs to the forkhead box
(Fox) transcription factor family and comprises FoxA1, FoxA2
and FoxA3. FoxA transcription factors are critical regulators of
tissue development, tissue function and metabolism4. In the
mammary gland, FoxA1 contributes to the differentiation of
luminal epithelial cells and co-regulates the hormonal response
to estrogen and androgen5–9. In liver and pancreas, FoxA
transcription factors are key controllers of metabolism8,9. Given
the role of FoxA1 in differentiation of luminal epithelial cells and
its transcriptional control of metabolic genes and pathways, we
study the potential function of FoxA family of transcription
factors in BCa metabolism.
Here we reveal that FoxA1 and the transcription factors family
regulate the expression of the endothelial lipase enzyme (LIPG), a
member of the lipoprotein lipase family. LIPG supports BCa cell
lipid addiction and loss of its activity impairs tumour growth.
Results
FoxA1 and FoxA2 in BCa growth. The importance of FoxA1 in
BCa cells differentiation and its contribution to controlling the
expression of metabolic genes in several other tissues makes this
transcription factor a highly attractive target to explain the
metabolic alterations reported in BCa. For these reason, we
decided to ascertain the metabolic processes controlled by FoxA1
in BCa. We ﬁrst conﬁrmed the association between high FoxA1
expression (mRNA and protein) and luminal subtype (Fig. 1a).
To this end, we used two cohorts of primary breast tumours with
annotated clinical features and follow-up. The MSKCC/EMC BCa
data set is based on gene expression proﬁles from an original
series of 560 cases10, whereas the Spanish BCa data set (n¼ 439)
is a tissue microarray of formalin-ﬁxed parafﬁn-embedded stage
I–III breast tumour specimens11 (details provided in Methods
Section). High FoxA1 gene expression signiﬁcantly correlated
with high expression of well-established luminal markers, such as
GATA3 and ESR1, in primary tumours (Supplementary Fig. 1a).
Next we explored FoxA1 expression beyond the luminal subtype.
Lower FoxA1 expression was observed in non-luminal tumours
(Fig. 1a,b); however, a subset also expressed higher FoxA1 levels
(Supplementary Fig. 1b and Supplementary Table 1). Given that
FoxA2, in conjunction with FoxA1, is also involved in the
regulation of several metabolic pathways, we determined the
expression of this factor in BCa samples. Unfortunately, no
FoxA2 probes in the Affymetrix platform used in the MSKCC/
EMC data set provided a reliable interpretation. To overcome this
limitation, we used tissue arrays of early BCa samples (Spanish
BCa set). Histological examination of FoxA2-stained tissue
microarray slides from the Spanish BCa set revealed the
expression of this factor in six non-luminal samples, which
were scored as FoxA1 (examples in Fig. 1b and summarized in
Supplementary Table 1). Collectively, the number of FoxAþ BCa
samples detected by immunohistochemistry accounted for 81.3%
of all samples in the Spanish BCa set (Supplementary Table 1),
which represent a signiﬁcant proportion of BCa and point to the
participation of FoxA in this disease, beyond to its involvement in
differentiation and control of hormonal responses.
Next, we extended our analysis to BCa cell lines for further
mechanistic studies. We compared FoxA1 and FoxA2 mRNA
expression in four estrogen receptor positive (ERþ ) (MCF7,
T47D, BT474 and ZR75) and four estrogen receptor negative
(ER ) (SKBR3, MDA468, BT20 and MDA231) BCa cell lines, a
cell line of melanoma origin (MDA435), and human mammary
epithelial cells (HMECs). Of note, two of the BCa lines tested
were HER2þ (BT474 and SKBR3) (Fig. 1c). All ERþ BCa cells
(MCF7, T47D, BT474 and ZR75), the ER /HER2þ SKBR3 and
both triple negative-like MDA468 and BT20 cell lines expressed
FoxA1. Interestingly, MDA231 triple negative-like cells expressed
high levels of FoxA2 but not FoxA1, and the non-tumour HMECs
did not express these factors (Fig. 1c). No BCa cells co-expressed
these two proteins (Fig. 1c). Our results suggest that the
expression of FoxA transcription factors is a common feature
of breast tumours, as well as of BCa cell lines. This notion implies
that FoxA factors play a major role in BCa growth, independently
of luminal fate speciﬁcation.
To examine the molecular basis of the contribution of FoxA1
and FoxA2 to BCa growth, we engineered constitutive
GFP-luciferase-expressing MCF7 and MDA231 cells with a
doxycycline-inducible short-hairpin RNA (sh-RNA) vector
targeting either FoxA1 or FoxA2. Doxycycline addition to the
cell culture media decreased FoxA expression in both cell lines
compared with control cells (ShControl (Doxþ ) and Sh FoxA1
or Sh FoxA2 (Dox ))(Fig. 1d), with the concomitant expression
of tRFP (Supplementary Fig. 1c). Of note, there was no gain of
expression of FoxA2 in FoxA1-depleted cells or vice versa
(Fig. 1d). Interestingly, cancer cell proliferation was impaired
in vitro upon depletion of either FoxA1 or FoxA2 in MCF7 and
MDA231 cells, respectively (Supplementary Fig. 1d,e). Similarly,
when Balb/c nude mice implanted with xenograft tumours from
the above described cellular populations were treated with
doxycycline and the short hairpins were induced, striking
differences in tumour growth were observed. FoxA1-depleted
MCF7 and FoxA2-depleted MDA231 tumour growth was blunted
(Fig. 1e and additional controls in Supplementary Fig. 1f.
Experimental details in the Supplementary Methods Section).
Collectively, these observations conﬁrm that FoxA1 or FoxA2
expression is required for BCa growth.
Previous studies indicate that FoxA1 and FoxA2 tran-
scriptionally regulate common genes in the liver and pancreas
that are central to development and metabolism. We therefore
hypothesized that crossed expression of FoxA factors could rescue
tumour growth by restoring the expression of essential metabolic
genes. To this end, we engineered doxycycline-driven shFoxA1
MCF7 cells to express exogenous FoxA2 and doxycycline-driven
shFoxA2 MDA231 cells to express exogenous FoxA1 (Fig. 1d).
Interestingly, when these BCa modiﬁed cells were implanted in
Balb/c nude mice and FoxA depletion was induced with
doxycycline, the sustained expression of another FoxA factor
(FoxA2 in MCF7 and FoxA1 in MDA231 cells) was sufﬁcient for
tumours to continuously grow (Fig. 1e and additional controls in
Supplementary Fig. 1f). Quantitative real-time PCR (qRT-PCR)
analysis conﬁrmed FoxA expression in the distinct tumour
populations ex-vivo (Supplementary Fig. 1g). These results
showed that retention of minimal levels of FoxA1 or FoxA2
expression is necessary for BCa cell growth.
FoxA1- and FoxA2-regulated transcripts for BCa growth. Next,
we focused on the identiﬁcation of genes under the control of
FoxA1 and FoxA2 with the capacity to support tumour growth in
xenograft tumours from implanted MCF7 and MDA231 cells,
with a speciﬁc focus on metabolic functions. To this end, we
isolated cells derived from non-depleted (Dox ) FoxA1 or
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FoxA2 MCF7 and MDA231 tumours (control groups, GFPþ /
tRFP ), FoxA1- and FoxA2-depleted MCF7 and MDA231
tumours (GFPþ /tRFPþ ), and the corresponding FoxA family-
rescued tumours (GFPþ /tRFPþ ), respectively (Fig. 2a).
Tumours surgically removed from the mouse were disaggregated
and GFP (cancer cell-speciﬁc), and tRFP expression (FoxA1- and
FoxA2-depleted cell-speciﬁc) was used to isolate human cancer
cells from mouse tumour stroma cells (Fig. 2a) in order to purify
RNA for subsequent transcriptomic analysis (GSE61164 and
Transcriptomic Analysis in Methods Section). Among the genes
under the control of FoxA1 and FoxA2 in the six cellular
populations, we identiﬁed LIPG and BCL2 as positively regulated
while CDH11 was negatively regulated (summarized in Fig. 2b;
details in Supplementary Table 2 and methods). We applied
stringent criteria to our analyses to prevent false positive hits (2.5-
fold change and false discovery rate o0.05). BCL2 expression is
associated with anti-apoptotic functions in cancer12, whereas
cadherin CDH11 induces apoptosis13. LIPG is an endothelial
lipase with phospholipase activity. It is involved in lipoprotein
metabolism, and its levels have been associated with testis
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Figure 1 | FoxA1 and FoxA2 in BCa growth. (a, top) FoxA1 mRNA expression in the MSKCC/EMC set. BCa samples were stratiﬁed in Luminal A, Luminal B,
Her2, triple negative and unknown subgroups. The unknown group represents specimens that were not classiﬁed in any group. (bottom) FoxA1 protein
levels by IHC staining in Luminal, Her2 and triple negative samples in the Spanish BCa set (cohort of 439 BCa patients). Data is average±s.d. (b) FoxA1
and FoxA2 IHC staining in FFPE human specimens representative of the different BCa subtypes. Six independent cases are depicted. FoxA1 and FoxA2 are
expressed mainly in the nuclei of tumour cells. Scale bar, 50mm. (c) FoxA1 and FoxA2 mRNA expression analysis by qRT-PCR and protein expression by
western blot in human BCa cell lines compared with HMECs. T-test was used. Data are average±s.e.m.; n¼ 3. Of note, MDA435 are of melanoma origin.
(d) FoxA1 and FoxA2 expression in MCF7, MDA231 and their derivatives cells by qRT-PCR and western blot. FoxA1 and FoxA2 depletion was achieved with
a doxycycline-inducible short hairpin vector. FoxA-depleted cells were rescued by expression of FoxA2 in MCF7 cells or FoxA1 in MDA231 cells. Cell
populations were cultured in the presence or absence of doxycycline for 6 days. P value is the result of T-test. Data are average±s.e.m.; n¼ 3. *Pr0.05,
***Pr0.001 (e, left) Schematic representation of MDA231 and MCF7 cells grown without doxycycline and inoculated in Balb/c nude mice treated with or
without doxycycline to induce the expression of the indicated FoxA short hairpins. All tumour cell lines have GFP constitutive expression, and tRFP
concomitantly with the short hairpin were expressed in doxycycline treated tumours. (right) Tumour growth of the indicated cell populations inoculated in
Balb/c nude mice are determined at the indicated time points. P value is the result of T-test. Data are average±s.e.m.; n¼ 5–8 tumours. *Pr0.05,
**Pr0.01, ***Pr0.001. FFPE, formalin-ﬁxed parafﬁn-embedded.
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cancer14–16. However, to date, LIPG has not been linked to
tumour growth. Robust changes in the mRNA expression of
LIPG, but not BCL2 or CDH11, were conﬁrmed by qRT-PCR
(Fig. 2c). Next, we conﬁrmed that FoxA factors regulate LIPG and
its promoter activity (Fig. 2c–e).
LIPG expression in BCa. Next, we showed that LIPG expression
in primary tumours was speciﬁc to BCa tumour cells and
not to other stroma cellular entities (Fig. 3a). Subsequently,
we tested LIPG expression in normal breast epithelia and
interrogated 20 samples from mammoplasty reductions.
Normal breast epithelial cells showed a lower expression of
LIPG than cells from tumour specimens (Fig. 3b). Similar results
were obtained for LIPG protein levels in a panel from BCa
lines compared with HMEC cells. Of the cellular populations
tested, the eight BCa cell lines expressing FoxA1 or FoxA2 had
very high levels of LIPG protein compared with the melanoma
MDA435 cell line and the human epithelial cell (Fig. 3c).
Consistent with this observation, 83.8% of BCa samples in the
Spanish tumour cohort were LIPGþ (Fig. 3d and Supplementary
Table 3), and LIPG expression correlated with FoxA expression
(Spearman correlation; r¼ 0.477, P¼ 0.000001; Fig. 3e).
Further analysis showed that LIPG expression levels in primary
tumours do not have the capacity to stratify patients for
differential risk of overall or disease-free survival (Supplementary
Fig. 2a) and are not dependent on estrogen signalling
(Supplementary Fig. 2b), thus reinforcing the notion that LIPG is
essential for BCa growth.
LIPG is a phospholipase located in the cytosol and cellular
membrane and has been shown to hydrolyse extracellular
phospholipids from high-density lipoprotein that are afterwards
incorporated into intracellular lipid species thus providing lipid
precursors of cell metabolism17,18. Thus we questioned whether
LIPG regulates essential lipid intake in BCa and whether it is
necessary for proliferation. To validate this hypothesis, we
genetically downregulated the expression of this protein in
MCF7 and MDA231 cells by means of sh-RNA (Fig. 3f and
Supplementary Fig. 2c). LIPG depletion blunted BCa cell capacity
to proliferate in vitro (Fig. 3f), as previously observed in
FoxA-depleted cells (Supplementary Fig. 1d,e), and caused a
reduction in invasion and self-renewal properties (Supplementary
Fig. 3a–d). Similarly, LIPG-depleted cells were unable to grow
tumours in vivo (Fig. 3g).
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Figure 2 | A genomic approach to identify FoxA1- and FoxA2-regulated transcripts in MCF7 and MDA231 cells. (a) FACS proﬁling of MCF7 and
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n¼ 5–8 tumours. *Pr0.05, ***Pr0.001. (d) LIPG protein expression in constitutive shFoxA1 MCF7 or shFoxA2 MDA231 cells. (e) Promoter reporter
assay in HEK 293 cells. Cells were transfected with LIPG promoter reporter and FoxA1 or FoxA2 expressing vectors when indicated. P value is the result of
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LIPG induces BCa cells lipid metabolic reprograming. Next, we
sought to identify whether the lack of LIPG caused a cellular
metabolic reprograming in the above selected BCa cell
models (MCF7 and MDA231 cells) (Fig. 4a). We used a liquid
chromatography-mass spectrometry-based untargeted lipidomic
analysis to compare LIPG-depleted versus control BCa cell
homogenates. This approach allowed us to quantify 47,000
metabolic features (deﬁned as molecular entities with a unique
mass/charge and retention time) in positive and negative
ionization modes. On the basis of accurate mass information,
altered metabolic features (P valueo0.05) in LIPG-depleted cells
accounted for 21% and 8% of the lipid landscape in MDA231 and
MCF7 cells, respectively. LIPG depletion induced a signiﬁcant
reduction in lipid species both in MCF7 and MDA231 cells
(that is, 85 and 96% of the altered species, respectively), the latter
involving a greater number of lipids (Supplementary Fig. 4a).
Supportingly, a reverse proﬁle is observed when LIPG gain of
function is evaluated (Supplementary Fig. 4b). Downregulated
lipid families in LIPG-depleted cells included mainly
glycerophospholipids such as phosphatyl ethanolamines (PEs)
and phosphatyl cholines (PCs), and glycerolipids such as
triacylglycerols (TGs) and diacylglycerols (DGs), as shown by
accurate mass information (Supplementary Fig. 4d). We next
structurally identiﬁed a large proportion of these lipids by means
of MS/MS experiments (Fig. 4b), which conﬁrmed the depletion
of PCs, LPCs, PEs, LPEs, PGs, DGs and MGs in MCF7 and
MDA231 cells. In particular, a speciﬁc LIPG lipid signature
shared by the two cell lines was found to include the following:
DG (40:2); DG (32:1); PE (32:2); PE (40:5); LPC (O-18:0);
LPC (16:0); and LPC (20:1) (Fig. 4c). Some of these lipid families
are pivotal in cancer malignancy19,20. Collectively, these
results suggest that LIPG shapes lipid metabolism in BCa cells
to support cellular growth requirements. Interestingly, FoxA
depletion in both MCF7 and MDA231 cells led to a lipid
metabolic reprograming similar to LIPG depletion
(Supplementary Fig. 4c–e).
LIPG location has been shown to be functional on the outer
face of the cellular membrane (Fig. 4a)18, thus we postulated the
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patients). (f) Left panel, in vitro proliferation curves of MCF7 and MDA231 cells transduced with a control or a LIPG short hairpin. Data are average±s.e.m.;
n¼ 3. (right) LIPG protein expression in shLIPG MCF7 and shLIPG MDA231 cells. The blot shown is representative of three independent experiments.
P value is the result of T-test.**Pr0.01, ***Pr0.001. (g) Tumour growth of the indicated cell populations inoculated in Balb/c nude mice are determined at
the indicated time points. P value is the result of T-test. Data are average±s.e.m.; n¼ 6–8 tumours. *Pr0.05.
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possibility that BCa cells are dependent on LIPG function to
access extracellular lipids to support their growth needs. To
test this notion, we proﬁled the media of control and LIPG-
depleted MCF7 and MDA231 cells following the same liquid
chromatography-mass spectrometry-based untargeted lipidomic
approach as for cell homogenates. LIPG depletion prevented the
absorption of particular lipids from the media (Supplementary
Fig. 4a). The structural identiﬁcation of the lipids by MS/MS
conﬁrms the absence of degradation of glycerophospholipids
belonging to the LPC class in both MCF7 and MDA231 cells,
which is depicted by higher levels in the media of these species in
LIPG-depleted when compared with control cells (Fig. 4d,e).
Interestingly when we analysed the LPCs species in the media of
control and LIPG-depleted cells and compared with fresh media
(without cells), all LPC species from control cell media were
decreased. This reduction was weaker in the media of Sh LIPG
cells, indicating that LIPG-depleted cells have a defect in
processing and importing of pre-existing lipid species from the
medium (Fig. 4f).
Finally, we evaluated which of the commonly identiﬁed potential
substrates of LIPG sustains BCa cell proliferation. Initially, we
conﬁrmed that the growth of MCF7 and MDA231 cells is impaired
when grown in vitro in lipoprotein-depleted media (Fig. 4g). Next
we tested the capacity of LPC (18:0) to rescue BCa cell growth in
the absence of lipoproteins and conﬁrmed that this lysopho-
sphatidylcholine was able to restore the cells’ capacity to proliferate
(Fig. 4g). In accordance, this process was dependent on LIPG
expression (Fig. 4g). Similarly, LIPG-depleted cells were not able to
grow in vivo in animals fed with high-fat diet (Fig. 4h) indicating
that LIPG is indispensable to process the extracellular lipids and
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mediate their uptake by the cells, irrespectively of the concentra-
tion of lipid substrates in circulation, a phenotype also observed in
FoxA-depleted cells (Fig. 4h).
LIPG activity supports BCa growth. The control of LIPG
expression by FoxA family transcription factors is likely to
increase the availability of lipids required for BCa cell membrane
synthesis and signalling cascades, thus facilitating the prolifera-
tion and growth of these cells, as well as other traits associated
with tumour progression and metastasis. To conﬁrm the central
role of LIPG activity in BCa tumour growth, and given the
overlapping phenotypes of cell growth impairment, we tested the
capacity of LIPG and its catalytic activity to rescue FoxA
depletion in tumour growth. To this end, we modelled the three–
dimensional (3D) structure of LIPG based on the structure of
other family members and conﬁrmed the presence of Asp193, key
residue from the catalytic domain of the human enzyme (Fig. 5a).
Indeed, the sole mutation of aspartic acid 193 to an asparagine
was sufﬁcient to inactivate LIPG21. Next, we genetically
engineered MCF7 and MDA231 cells containing the
doxycycline-driven FoxA1 or FoxA2 sh-RNA expression system
and transduced them with either a catalytically active or inactive
LIPG expression vector (Fig. 5b). Then, 1 106 cells were injected
into Balb/c nude mice treated with or without doxycycline
(Fig. 5c). Remarkably, the effect of FoxA1 or FoxA2 depletion on
tumour growth was rescued only in tumours expressing
exogenous wild-type (WT) LIPG but not in those with a
catalytically inactive form of the protein (Fig. 5c and additional
controls in Supplementary Fig. 5a). Furthermore, gene expression
analysis conﬁrmed FoxA depletion and LIPG expression in the
tumour populations at the end point of the tumour growth
experiment and the rescue was also conﬁrmed in cell culture
(Supplementary Fig. 5b,c). Overall, these results suggest that BCa
growth requires exogenous lipid precursors and that these are
provided, in part, by LIPG activity.
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As previous reports showed that de novo lipid metabolism is
necessary for BCa growth3,22, we next questioned whether this
lipid synthesis was sufﬁcient or, instead, whether exogenous
sources are also required to support BCa cell growth and
proliferation, as suggested by our experimental data. To this end,
we inhibited the activity of fatty acid synthase (FAS) in BCa cells
by means of the chemical inhibitor C75 (ref. 23). FAS activity is
crucial for de novo lipid synthesis in cancer cells3,22. To test the
complementarity of both de novo and/or exogenous lipid supplies,
we used a C75 concentration causing a 50% reduction in BCa cell
growth in vitro 48h post incubation (Fig. 5d and Supplementary
Fig. 5d). Similarly, we tested the contribution of LIPG inhibition
by means of treatment with a lipase inhibitor, Orlistat21. A
speciﬁc dose causing a 50% reduction in the growth of each BCa
cell line was further used (Fig. 5d and Supplementary Fig. 5d).
Interestingly, concomitant treatment with FAS and LIPG
inhibitors caused an additive effect, blunting BCa cell growth
(Fig. 5d). Next, we evaluated whether LIPG activity was sufﬁcient
to rescue the chemical inhibition of FAS. To this end, we
overexpressed WT and inactive LIPG and grew MCF7 and
MDA231 cells in the presence or absence of a high dose of C75
(20mgml 1), which blocks cell growth (Supplementary Fig. 5d).
Complete blockade of FAS was not rescued by LIPG (Fig. 5e).
Collectively, our results suggest that both exogenous lipid
precursors provided by means of LIPG activity and de novo lipid
synthesis mediated by FAS are necessary for BCa cell growth.
Discussion
Here we reveal that FoxA factors provide a central metabolic
growth function by speciﬁcally regulating LIPG expression,
thereby allowing the acquisition of indispensable extracellular
lipids for BCa tumour proliferation. FoxA family of transcription
factors are expressed in the vast majority of BCa and FoxA1 is
expressed across various BCa subtypes. Moreover we show that,
in some cases, its absence is associated with the expression of
FoxA2. Interestingly, in addition of FoxA1 contribution to
luminal commitment24–27 the factor may drive BCa growth by
speciﬁcally regulating LIPG levels.
The catalytic activity of LIPG generates extracellular lipid
precursors that are imported to fulﬁll the intracellular production
of lipid species (Fig. 5f). LIPG downregulation blocks BCa cell
growth, thereby indicating that the import of extracellular lipid
precursors is important for the proliferation of these cells. This is
a striking observation given that it is generally believed that de
novo fatty acid synthesis is the main driver of tumour growth22.
Indeed, our experimental data with LIPG-depleted BCa cells
revealed a massive decrease of most intracellular glycerolipid
intermediates in the synthesis of TG (PC, PE, PG and DG) and
their derivatives (LPC and LPE). Accordingly, certain lipid species
(LPC) in the media were not decreased in LIPG-depleted cells as
much as in control cells, thus indicating that extracellular
lipids are the substrates for intracellular lipid production. In
particular, we demonstrate the relevance of extracellular LPC
(18:0) for BCa cell proliferation in a lipoprotein-depleted
medium, a process dependent on LIPG. In this context, a high-
fat diet was shown to rescue the absence of a critical intracellular
lipase, Monoacylglycerol lipase, for cancer pathogenesis given
cancer cells ability to uptake lipids from the extracellular
compartment was functional19. Herein, we showed that this
rescue mechanism is not functional in BCa cells in the absence of
FoxA2 or LIPG. In support of this notion, it is worth noting that
extracellular LIPG activity releases fatty acids from high-density
lipoprotein phospholipids and these acids are further employed
for intracellular lipid production in the human hepatic cell line
HepG2 (refs 28,29).
In conclusion, BCa cells are dependent on a mechanism to
supply precursors derived from extracellular sources for
intracellular lipid production, and LIPG fulﬁlls this function.
Therefore, LIPG stands out as an important component of the
lipid metabolic adaptations that BCa cells, and not normal tissue,
must undergo to support high proliferation rates. Our results also
suggest that de novo lipid synthesis is necessary but not sufﬁcient
to support lipid production for BCa tumour growth. Accordingly,
recent clinical studies demonstrate the association between
lipids and lipoproteins in circulation and risk of BCa in women
with extensive mammographic density. This observation implies
that interventions aimed to reduce them may have effect on
BCa risk30. All together, these observations make LIPG activity
an Achilles heel of luminal and, more importantly, of triple
negative/basal-like breast tumours, for which limited therapeutic
options are currently available.
Methods
Breast cancer cell lines. HMECs were purchased from Lonza and MDA-MB-468,
ZR75, MDA-MB-435, MDA-MB-231, MCF7, T47D, BT20 and BT474 cells from
ATCC. MDA-MB-435 was used to test BCa cell lines speciﬁcity as it is reported to
be a melanoma. All cells, except HMECs, were maintained in DMEM supple-
mented with 10% FBS, 100mgml 1 streptomycin, 100Uml 1 penicillin and
2mM L-glutamine. HMECs were maintained in mammary epithelial growth
medium (Lonza). Cells were tested for mycoplasma monthly as per laboratory
routine.
Western blot and qRT-PCR analysis. For FoxA1 and FoxA2 detection, cells were
lysed with a buffer containing (10% SDS, 60mM Tris pH 6.8 and 7% DTT). For
LIPG detection, cells were lysed using a buffer containing 25mM Tris-HCl pH 7.4,
25mM NaCl 1% (v/v), Triton X-100, 0.1% SDS, 10mM NaF, 10mM PPi, 1mM
sodium orthovanadate, 0.5mM EGTA and 20 nM oxadaic acid supplemented with
protease and phosphatase inhibitors (Sigma Aldrich). Equal amounts of protein per
sample were separated by standard SDS–polyacrylamide gel electrophoresis and
transferred to immobilon membranes (Millipore). The membranes were incubated
with FoxA1 (Millipore), LIPG (Abcam), FoxA2 (Cell Signaling), ESR1 (Abcam) or
actin (Sigma). FoxA1, FoxA2, LIPG and ESR1 antibodies were used at a dilution of
1:1,000 and Actin at a dilution of 1:25,000. To assess changes in expression of selected
genes, qRT-PCR was performed using the comparative CT method and an ABI
Prism Fast 7900 HT instrument (PE Applied Biosystems). Ampliﬁcation was per-
formed using TaqMan Gene Expression Assays (Applied Biosystems), following the
manufacturer’s instructions. FoxA1 (Hs00270129-m1), FoxA2 (Hs00232764-m1),
LIPG (Hs00195812-m1) and 18S (Hs99999901-s1) were purchased from Applied
Biosystems. All assays were done in triplicate, and 18S mRNA was used as an
endogenous control for normalization. Results were analysed using SDS2.3 software
(PE Applied Biosystems).
Overexpression and mutagenesis. Overexpression of FoxA1, FoxA2 and LIPG
was achieved by lentivirus. Brieﬂy, the human ORF of each protein was purchased
from Open Biosystem, and cDNA was made to obtain a PCR product with
recombination arms for insertion in a p-entry clone p221 using the gateway system.
FoxA1 primers (Fw: 50-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACC
ATGTTAGGAACTGTGAAG ATGGAAGG-30 ; Rev: 50-GGGGACCACTTTGT
ACAAGAAAGCTGGGTTCTAGGAAGTGTTTAG GACGGGTCTGG-30), FoxA2
primers (Fw: 50-GGGGACAAGTTTGTACAAAAAAGCAGGCTTC ACCATGCT
GGGAGCGGTGAAGATGGAAGG-30; Rev: 50-GGGGACCACTTTGTACAAGA
AAGC TGGGTTTTAAGAGGAGTTCATAATGGGCCGGGA-30, and LIPG
primers (Fw: 50-GGGGACAAGT TTGTACAAAAAAGCAGGCTTCACCATG
AGCAACTCCGTTCCTCTGCTCTG-30 , Rev: 50-GGGGAC CACTTTGTACAAG
AAAGCTGGGTTTCAGGGAAGCTCCACAGTGGGACTGG-30. After conﬁrma-
tion of cDNA sequence ﬁdelity, the cDNA was transferred into a p-lenti vector
using a gateway system. Afterwards, HEK293T cells were seeded and transfected
with lentiviral packaging plasmids and the p-lenti FoxA1, FoxA2 or LIPG vectors.
The supernatants of the cells were collected, and MCF7 and MDA231 cells were
infected and selected with 5 mgml 1 hygromycin to obtain a stable resistant
population.
Catalytically inactive LIPG was generated by site-direct mutagenesis using the
template p-entry plasmid p221-LIPG, primers (Fw: 50-CGAATCACAGGTTTGA
ATCCTGCCGGGCC-30); (Rev: 50-GGCCCGGCAGGATTCAAACCTGTG
ATTCG-30), and the QuikChange XL Site-directed Mutagenesis Kit (Stratagene).
Mutation of aspartic acid 193 to an asparagine was conﬁrmed by DNA sequencing,
and the ORF with the mutation was transferred to the p-lenti vector as described
before.
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Transcriptomic analysis. Generation of biotinylated complementary RNA
(cRNA) probes from RNA samples was achieved following the standard Affymetrix
(Santa Clara, CA) GeneChip protocol. cRNA probe was prepared using Total RNA
(10 mg) and employing a Custom Superscript Kit (Invitrogen). Isothermal ampli-
ﬁcation SPIA Biotin System (NuGEN Technologies), for expression proﬁling, was
achieved using 25 ng of RNA per sample. Samples were hybridized with a Gen-
eAtlas Human Genome U-219 array, and Bioconductor was used to generate the
statistical analyses for the microarrays31. Quantile normalization, background
correction, and RMA summarization was achieved following Bioconductor’s Affy
package instructions. Hybridization was performed at IRB Barcelona’s Functional
Genomics Facility and statistical analyses at IRB Barcelona’s Biostatistics/
Bioinformatics Facility.
Comparative genome-wide analysis yielded two hits of genes positively
regulated by FoxA1 and FoxA2 (GSE61164). The genes of interest were selected on
the basis of the following criteria: (1) decreased expression in MCF7 and MDA231
cells upon FoxA depletion compared with control cells; and (2) increased
expression in MCF7 and MDA231 FoxA-rescued cells compared with the
respective FoxA-depleted population. In contrast, to classify a gene transcript as
negatively regulated by FoxA, we established that a gene probe must meet the
following criteria: (1) increased expression in MCF7 and MDA231 cells upon FoxA
depletion compared with control cells; and (2) decreased expression in MCF7 and
MDA231 FoxA-rescued cells compared with the respective FoxA-depleted
population.
All changes were computed when a42.5 fold change, positive or negative, with
a Bayesian false discovery rate below 5% was reached (Supplementary Table 2 and
summarized in Fig. 2b). False discovery rates were calculated using a semi-
parametric empirical Bayes32 procedure based on moderated t-tests33 as
implemented in the limma package of Bioconductor.
Short hairpin studies in cells and proliferation assays. Brieﬂy, HEK293T cells
were seeded and transfected with lentiviral packaging plasmids and TRC1 sh clones
for LIPG (50-CCGGGCCGCAAGAACCGTTGTAATACTCGAGTATTACAACG
GTTCTTGCGGCTTTTTG-30), FoxA1 (50-CCGGGAACACCTACATGACC
ATGAACTCGAGTTCATGGTCATGTAGGTGTTCTTTTT-30) or FoxA2 (50-CC
GGGCCCATTATGAACTCCTCTTACTCGAGTAAGAGGAGTTCATAATGG
GCTTTTT-30), all purchased from Sigma Aldrich. MCF7 and MDA231 cells were
infected and selected with 5 mgml 1 puromycin to obtain a stable resistant
population that were used for experiments in the following 10 days after selection.
After selection, they were recovered with fresh medium, and 105 cells were plated
in six-well culture plates. At each time point, cells were trypsinized, collected, and
counted using a Scepter 2.0 Cell Counter.
Breast cancer cell growth in lipoprotein-free medium. 5 105 MCF7 and
MDA231 cells were plated in six-well culture plates and incubated O/N in
Dulbecco´s modiﬁed Eagle´s medium (DMEM) supplemented with 10% lipoprotein-
free FBS (Gibco), 100mgml 1 streptomycin, 100Uml 1 penicillin and 2mM
L-glutamine. Then, the medium was replace by: complete medium: DMEM
supplemented with 10% FBS (Gibco), 100mgml 1 streptomycin, 100Uml 1
penicillin and 2mM L-glutamine; lipoprotein-free medium: DMEM supplemented
with 10% lipoprotein-free FBS (Gibco), 100mgml 1 streptomycin, 100Uml 1
penicillin, and 2mM L-glutamine, Transferrin (10 mgml 1), Triiodothyronine
(0,01 mM) (Sigma), o-phosphorylethanolamine (5 mgml 1) (Sigma), glutathione
(0,012 mgml 1) (Sigma), hydrocortisone (0,5 mgml 1) (Sigma), EGF
(10 ngml 1) (RD), FGF (10 mgml 1) (Gibco), Insulin (20mgml 1),
medroxiprogesterone (10 nM) (Sigma) and BSA-free fatty acids 0,5% (Sigma); LPC
(18:0) medium: lipoprotein-free medium supplemented with 20 mM LPC 18:0
(Avanti polar). LPC 18:0 was dissolved in water. The same three media were used
in cells depleted of LIPG. After 48 h of incubation cells were trypsinized, collected
and counted using a Scepter 2.0 Cell Counter.
In vitro drug assays. A total of 5 105 MCF7 and MDA231 cells were plated in
six-well culture plates and incubated O/N in DMEM supplemented with 10%
lipoprotein-free FBS (Gibco), 100mgml 1 streptomycin, 100Uml 1 penicillin
and 2mM L-glutamine. Then the media was replace by, complete medium: DMEM
supplemented with 10% FBS (Gibco), 100mgml 1 streptomycin, 100Uml 1
penicillin and 2mM L-glutamine supplemented with Orlistat (Sigma), (C75 Sigma)
or a combination of both drugs. Both drugs were resuspended in DMSO following
manufacture indications. Concentrations of drugs are indicated in the ﬁgure
legends. After 48 h of incubation cells were trypsinized, collected, and counted
using a Scepter 2.0 Cell Counter. For tamoxifen treatment cells were plated
and incubated in DMEM supplemented with 0,5% FBS (Gibco), 100mgml 1
streptomycin, 100Uml 1 penicillin and 2mM L-glutamine supplemented with
tamoxifen (6mM) for 24 h.
Reporter assays. Renilla and luciferase reporter assays were performed as
previously described34. The plasmid p-lightSwitch-Promo-Renilla containing the
LIPG promoter was used (SwitchGear Genomics, ID:S715324). SFG-TGL
Luciferase plasmid (Promega) was included to control for transfection efﬁciency.
Inducible sh-RNA systems. The inducible sh-RNA systems were generated as
described35. First, we selected a hairpin sequence from constitutive short hairpins
(TRC1 sh clones Sigma Aldrich, LIPG (50-CCGGGCCGCAAGAACCGTTG
TAATACTCGAGTATTACAACGGTTCTTGCGGCTTTTTG-30); FoxA1(50-CC
GGGAACACCTACATGACCATGAACTCGAGTTCATGGTCATGTAGGTGT
TCTTTTT-30); FoxA2(50-CCGGGCCCATTATGAACTCCTCTTACTCGAGTA
AGAGGAGTTCATAATGGGCTTTTT-30) known to work for FoxA1 or FoxA2.
We designed and ordered a template oligonucleotide by incorporating miR-30
micro RNA sequences between the sense and the antisense sequence of the selected
hairpin and then ampliﬁed the fragment to incorporate EcoRI and Xhol cloning
sites. The PCR product was isolated from a PCR gel with ILLUSTRA GFX PCR
DNA and the Gel Band Puriﬁcation Kit (GE Healthcare) and digested with EcoRI
and Xhol at 15–25 C. The digested product was inserted in a p-Triptz vector, and
the ligation reaction was transformed into competent bacteria, which were selected
in the presence of ampicillin. Afterwards, HEK293T cells were seeded and
transfected with lentiviral packaging plasmids and the generated ptriptz-sh
FoxA1- or ptriptz-sh FoxA2-inducible vectors. MCF7 and MDA231 cells were
infected with the above-mentioned vectors and selected with 5 mgml 1 puromycin
to obtain a stable resistant population.
Adhesion assay. Cells were labelled with 5 mM of cell Tracker green (Invitrogen),
following the manufacturer’s instructions, and kept overnight in medium without
FBS. Next day, 5 104 cells were seeded in triplicates on 10 mgml 1 collagen I- or
ﬁbronectin-coated 24-well plates dissolved in DMEM. Two hours (in the case of
MDA-MB-231) or 3 hours (in the case of MCF7) after seeding, cells were washed
carefully with PBS and ﬁxed with 4% formalin. Cells were visualized and counted
using the Olympus ScanR- Xcellence-TIRF wideﬁeld ﬂuorescence microscope.
Each well was segmented in 11 11 squares (in total 121), and one image per
square was taken. Images and counting were processed with a custom macro
created by Anna Llado´ from the Advanced Digital Microscopy Core Facility at IRB
Barcelona and designed for the Fiji program. The total number of cells per well is
shown. A two-tail Mann–Whitney unpaired t-test was used to analyse statistical
differences between groups.
Migration assay. Cells were marked with 5 mM of cell Tracker green (Invitrogen),
following the manufacturer’s instructions, and kept overnight in medium without
FBS. Next day, 5 104 cells were seeded in triplicates on ﬁbronectin-coated BD
Biocat Cell Culture Inserts (BD Bioscience, cat no 354543) in medium without FBS,
while the wells were loaded with complete medium. Before seeding, inserts were
hydrated with 250 ml of medium for 30min at 37 C. Eight hours after seeding, cells
were washed with PBS and ﬁxed with 4% formalin. Cells on the apical side of each
insert were scraped off, and migration to the basolateral side was visualized with an
Olympus ScanR- Xcellence-TIRF wideﬁeld ﬂuorescence microscope. Each insert
was segmented in 6 6 squares (in total 36), and one image per square was taken.
The images shown are the result of the 36 pictures stitched using a custom macro
created by Anna Llado´ and Sebastian Tosi from the Advanced Digital Microscopy
Core Facility at IRB Barcelona and designed for the Fiji program. Cell counting was
processed with another custom macro created by Anna Llado´. The total number of
cells per  4 ﬁeld in each well is shown. A two-tail Mann–Whitney unpaired t-test
was used to analyse statistical differences between groups.
Invasion assay. Cells were marked with 5 mM of cell Tracker green (Invitrogen),
following the manufacturer’s instructions, and kept overnight in medium without
FBS. Next day, 5 104 cells were seeded in triplicates on Matrigel Invasion
Chambers (BD Bioscience, cat no 354480) in medium without FBS, while the wells
were loaded with complete medium. Before seeding, inserts were hydrated with
500 ml of medium for 2 h at 37 C. Eight hours after seeding, cells were washed with
PBS and ﬁxed with 4% formalin. Cells on the apical side of each insert were scraped
off, and migration to the basolateral side was visualized with an Olympus ScanR-
Xcellence-TIRF wideﬁeld ﬂuorescence microscope. Each insert was segmented in
6 6 squares (in total 36), and one image per square was taken. The images shown
is the result of the 36 pictures stitched using a custom macro created by Anna
Llado´ and Sebastian Tosi from the Advanced Digital Microscopy Core Facility in
IRB Barcelona and designed for the Fiji program. Cell counting was processed with
another custom macro created by Anna Llado´. Total number of cells per  4 ﬁeld
in each well is shown. Two tails Mann–Whitney unpaired t-test was used to analyse
statistical differences between groups.
Oncosphere formation assay. Cells were collected, and 1 cell per well was sorted
into ultra-low attachment 96-well plates (Costar, cat no 3474). Cells were cultured
in suspension in the following media: mammary epithelial basal medium (MEBM,
LONZA cat no. CC-3151), supplemented with MEGM Single-Quots (containing
EGF, Hydrocortisone, Insulin and GA-1000, LONZA cat no. 4136), 20 ngml 1 of
recombinant ﬁbroblast growth factor (GIBCO, cat no. PHG0026) and 1X B27
without retinoic acid (GIBCO, cat no. 12787-010). Plates were placed at 37 C, 5%
CO2 for 15 days. Quantiﬁcation was performed manually, counting total number of
oncospheres under the microscope. A two-tail Mann–Whitney unpaired t-test was
used to analyse statistical differences between groups.
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Organotypic formation assay. To form 3D organoids, cells were mixed in
growth-reduced factor matrigel (BD Bioscience, cat no. 354230) in a concentration
of 2,000 cells per 25 ml of matrigel. Each drop was dispensed in the center of the
well from adherent 48-well plate and incubated for 15min at room temperature.
After matrigel is solidiﬁed, 250 ml of oncosphere assay media (see above) was added
to each well. Every other day, media was changed, and organotypic 3D structures
were grown for a total of 15 days. The total number of organoids was counted using
a custom macro created by the Advance Digital Microscopy Core Facility at IRB
Barcelona. The images shown are the result of the 42 pictures stitched (which
recreates the whole drop) using a custom macro created by the Advanced Digital
Microscopy Core Facility at IRB Barcelona and designed for the Fiji program.
A two-tail Mann–Whitney unpaired t-test was used to analyse statistical differences
between groups.
Experimental procedures for patient data sets. We used the MSK-82 and
EMC-344 data sets, which are based on HG-U133A and were combined, and the
EMC-189 data set, which is based on HG-U133plus2 and was processed separately
(GSE2603, GSE12276, GSE5327 and GSE2034 available at the Gene Expression
Omnibus (GEO) public database). To remove systematic biases, the expression
measurements were converted to z-scores for all genes before merging. Patient
clinical records of the 615 primary tumour samples were extracted from supple-
mental material described by Zhang et al. ‘Latent bone metastasis in BCa tied to
Src-dependent survival signals’36. Following the indications of the Cancer Cell
manuscript (Supplementary Table 1, page 33 of Supplementary Material), we
retrieved the metastasis site annotation from Table 8 of Bos et al. ‘Genes that
mediate BCa metastasis to the brain10. The site of metastasis annotation was
available for 560 out of the 615 samples. The median follow-up among all 560
patients was 4 years (range 0–14.25). The 55 patients with no time to metastasis
reported were not included at any ulterior time after metastasis analysis. The
median duration of follow-up was 7.667 years (range 0–14.25) for the 268 patients
without metastasis and 1.917 years (range 0–9.583) for the 292 patients with
metastasis.
As described elsewhere37, tumour specimens and mammoplasties were obtained
from the Parc de Salut Mar Biobank (MARBiobanc, Barcelona, Spain), and the
Valencia Clinic Hospital Biobank (Valencia, Spain), the Fundacio´n Jime´nez
Dı´az Biobank (Madrid, Spain). Primary breast tumours from formalin-ﬁxed
parafﬁn-embedded blocks were retrospectively selected from consecutive patients
diagnosed between 1998 and 2000. The following criteria were required for patients
enrollment: no neoadjuvant therapy; inﬁltrating carcinomas; operable; sufﬁcient
tissue for research purposes once fulﬁlled all clinical needs; and clinical follow-up.
Normal breast tissue cases (n¼ 20) were obtained from non-cancerous
mammoplasties.
Tumour–node–metastasis was categorized using the staging system of the
American Joint Committee on Cancer (AJCC). ER and PR were assessed by
immunohistochemistry (IHC) (SP1 and PgR636 clones, respectively; Dako,
Carpinteria, CA) establishing positivity criteria inZ1% of nuclear tumour staining.
Histological grade was deﬁned following Scarff–Bloom–Richardson modiﬁed by
Elston and Ellis, Histopathology (1991) 19: 403-410. FISH assays were used for
HER2 ampliﬁcation (PathVysion; Abbott Laboratories, Abbott Park, IL). Ki-67 was
analysed by IHC (MIB1 clone; Dako). BRCA1 and BRCA2 gene status was tested in
patients that required genetic counseling. The Ethics Committees of the three
hospitals approved the study and informed consent from all subjects was secured.
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